Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study : lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study : lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study : lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma
author:
Arcaini Luca, Lamy Thierry, Walewski Jan, Belada David, Mayer Jiri, Jurczak Wojciech , Morschhauser Franck, Alexeeva Julia, Rule Simon, Cabeçadas José, Campo Elias, Pileri Stefano A., Biyukov Tsvetan, Patturajan Meera, Casadebaig Bravo Marie-Laure, Trněný Marek
Except where otherwise noted, this item's license is described as Udzielam licencji. Uznanie autorstwa - Użycie niekomercyjne - Bez utworów zależnych 4.0 Międzynarodowa